MA41817A - NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT - Google Patents

NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT

Info

Publication number
MA41817A
MA41817A MA041817A MA41817A MA41817A MA 41817 A MA41817 A MA 41817A MA 041817 A MA041817 A MA 041817A MA 41817 A MA41817 A MA 41817A MA 41817 A MA41817 A MA 41817A
Authority
MA
Morocco
Prior art keywords
oxazino
benzotriazine
antidepressant
dione
fluorophenyl
Prior art date
Application number
MA041817A
Other languages
English (en)
Inventor
Sylvie Bretin
Laurence Danober
Pierre Lestage
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA41817A publication Critical patent/MA41817A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA041817A 2015-03-26 2016-03-24 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT MA41817A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (fr) 2015-03-26 2015-03-26 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
MA41817A true MA41817A (fr) 2018-01-30

Family

ID=53776719

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041817A MA41817A (fr) 2015-03-26 2016-03-24 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT

Country Status (12)

Country Link
EP (1) EP3273996A1 (fr)
JP (1) JP2018509436A (fr)
KR (1) KR20170125835A (fr)
AU (1) AU2016238625A1 (fr)
CA (1) CA2975571A1 (fr)
FR (1) FR3034019B1 (fr)
MA (1) MA41817A (fr)
PH (1) PH12017501248A1 (fr)
SG (1) SG11201706076QA (fr)
TN (1) TN2017000280A1 (fr)
WO (1) WO2016151265A1 (fr)
ZA (1) ZA201705052B (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578293A (en) * 2007-01-03 2012-01-12 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
FR3034019B1 (fr) 2017-03-17
JP2018509436A (ja) 2018-04-05
SG11201706076QA (en) 2017-08-30
WO2016151265A1 (fr) 2016-09-29
TN2017000280A1 (fr) 2019-01-16
KR20170125835A (ko) 2017-11-15
AU2016238625A1 (en) 2017-08-03
FR3034019A1 (fr) 2016-09-30
ZA201705052B (en) 2019-02-27
CA2975571A1 (fr) 2016-09-29
EP3273996A1 (fr) 2018-01-31
PH12017501248A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
PT3453707T (pt) Derivado de benzazepina, método de preparação, composição farmacêutica e a sua utilização
ZA201900470B (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
HK1255566A1 (zh) 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
GB201913962D0 (en) Ophthalmic drug compositions
IL254098A0 (en) Compressed ring derivatives and method of preparation, intermediates, pharmaceutical preparations and their use
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
GB201807968D0 (en) Eutectic extract formation and purification
IL272638A (en) History of quinoxaline, their preparation and pharmaceutical preparations containing them
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
IL262745A (en) Improved preparations containing drugs
PT3606511T (pt) Composição farmacêutica compreendendo mesilato de lenvatinib
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
IL283450A (en) capsule formulations
ZA201908006B (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
PL3313370T3 (pl) Okulistyczna kompozycja farmaceutyczna
IL266859A (en) Solid oral composition containing dyes
PL3176164T3 (pl) Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem
EP3441075A4 (fr) Composition d'huile essentielle administrée par voie orale et son utilisation
MA41817A (fr) NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
GB201505938D0 (en) Compositions comprising C0-Q10, krill oil and vitamin D
FR3019464B1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
GB201520226D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methodsof use thereof.